Trials / Unknown
UnknownNCT05975164
the Real World Study of Orelabrutinib in the Treatment of CLL/SLL
A Retrospective Real-world Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Multicenter, Retrospective Real-world Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
Detailed description
Orelabrutinib is a novel BTK inhibitor with high selectivity and has been approved in China for relapsed/refractory CLL/SLL,, The purpose of this study is to describe the effectiveness and safety of orelabrutinib of chronic lymphocytic leukemia (CLL) in real world.
Conditions
Timeline
- Start date
- 2023-07-25
- Primary completion
- 2023-12-10
- Completion
- 2024-07-10
- First posted
- 2023-08-03
- Last updated
- 2023-08-03
Source: ClinicalTrials.gov record NCT05975164. Inclusion in this directory is not an endorsement.